Cargando…

Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study

BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China....

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Qin, Wang, Yu-Zhen, Kan, Lian-Di, Chen, Jie, Wang, Chen, Han, Gang, Li, Liu-Cheng, Lou, Wei-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983439/
https://www.ncbi.nlm.nih.gov/pubmed/36875172
http://dx.doi.org/10.2147/RMHP.S392224
_version_ 1784900546863300608
author Qian, Qin
Wang, Yu-Zhen
Kan, Lian-Di
Chen, Jie
Wang, Chen
Han, Gang
Li, Liu-Cheng
Lou, Wei-Jian
author_facet Qian, Qin
Wang, Yu-Zhen
Kan, Lian-Di
Chen, Jie
Wang, Chen
Han, Gang
Li, Liu-Cheng
Lou, Wei-Jian
author_sort Qian, Qin
collection PubMed
description BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China. METHODS: In this study, the demographic, diagnosis, and medication prescription data including the antihypertensive drug types and comorbidities, were analyzed. The antihypertensive drugs use were evaluated according to the Chinese guidelines for hypertension. RESULTS: 1301 prescriptions (number of visits) containing 1880 antihypertensive medical orders were collected. The average number of antihypertensive drugs per prescription was 1.45 (±0.75). The patients aged 16 to 18 (70.18%) accounted for the highest proportion. Kidney diseases (33.28%) were the most common comorbidities. Calcium channel blocker (CCB), angiotensin II receptor blocker (ARB), and β receptor blocker (BB) were the most used antihypertensive drugs. The most frequent monotherapy was CCB, while that of two and three drugs combination were ARB+CCB and ARB+BB+CCB, respectively. Metoprolol (11.44%), nifedipine (10.64%), amlodipine (10.59%), valsartan (6.12%) were the most commonly used antihypertensive drugs. The utilization rate of fixed compound preparations was 7.34%. However, the percentage of recommended antihypertensive drugs was just 14.20%, while the recommended drug combination was 84.93% according to the guidelines. CONCLUSION: For the first time ever we reported the antihypertensive prescription analysis in children in a large area of China. Our data provided new insights into the epidemiological characteristics and drug use in hypertensive children. We found that the guidelines for medication management in hypertensive children were not routinely followed. The wide use of antihypertensive drugs in children and those with weak clinical evidence raised concerns regarding its rational use. The findings could lead to more effective management of hypertension in children.
format Online
Article
Text
id pubmed-9983439
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99834392023-03-04 Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study Qian, Qin Wang, Yu-Zhen Kan, Lian-Di Chen, Jie Wang, Chen Han, Gang Li, Liu-Cheng Lou, Wei-Jian Risk Manag Healthc Policy Original Research BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China. METHODS: In this study, the demographic, diagnosis, and medication prescription data including the antihypertensive drug types and comorbidities, were analyzed. The antihypertensive drugs use were evaluated according to the Chinese guidelines for hypertension. RESULTS: 1301 prescriptions (number of visits) containing 1880 antihypertensive medical orders were collected. The average number of antihypertensive drugs per prescription was 1.45 (±0.75). The patients aged 16 to 18 (70.18%) accounted for the highest proportion. Kidney diseases (33.28%) were the most common comorbidities. Calcium channel blocker (CCB), angiotensin II receptor blocker (ARB), and β receptor blocker (BB) were the most used antihypertensive drugs. The most frequent monotherapy was CCB, while that of two and three drugs combination were ARB+CCB and ARB+BB+CCB, respectively. Metoprolol (11.44%), nifedipine (10.64%), amlodipine (10.59%), valsartan (6.12%) were the most commonly used antihypertensive drugs. The utilization rate of fixed compound preparations was 7.34%. However, the percentage of recommended antihypertensive drugs was just 14.20%, while the recommended drug combination was 84.93% according to the guidelines. CONCLUSION: For the first time ever we reported the antihypertensive prescription analysis in children in a large area of China. Our data provided new insights into the epidemiological characteristics and drug use in hypertensive children. We found that the guidelines for medication management in hypertensive children were not routinely followed. The wide use of antihypertensive drugs in children and those with weak clinical evidence raised concerns regarding its rational use. The findings could lead to more effective management of hypertension in children. Dove 2023-02-27 /pmc/articles/PMC9983439/ /pubmed/36875172 http://dx.doi.org/10.2147/RMHP.S392224 Text en © 2023 Qian et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qian, Qin
Wang, Yu-Zhen
Kan, Lian-Di
Chen, Jie
Wang, Chen
Han, Gang
Li, Liu-Cheng
Lou, Wei-Jian
Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title_full Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title_fullStr Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title_full_unstemmed Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title_short Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
title_sort real-world prescribing patterns for hypertensive children in china from 2018 to 2021: a cross-sectional multicenter study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983439/
https://www.ncbi.nlm.nih.gov/pubmed/36875172
http://dx.doi.org/10.2147/RMHP.S392224
work_keys_str_mv AT qianqin realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT wangyuzhen realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT kanliandi realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT chenjie realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT wangchen realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT hangang realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT liliucheng realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy
AT louweijian realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy